Detection of Aβ oligomers based on magnetic-field-assisted separation of aptamer-functionalized Fe 3 O 4 magnetic nanoparticles and BaYF 5 :Yb,Er nanoparticles as upconversion fluorescence labels

Jiang, Linfeng; Chen, Bo-Cheng; Chen, Ben; Li, Xuejian; Liao, Hai; Huang, Hongmiao; Guo, Zhanjing; Zhang, Wenyan; Wu, Lin

doi:10.1016/j.talanta.2017.04.021

Cited by 47 publications

(19 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To illustrate the ability of the dLFI in Aβ detection, a horizontal comparison of various available technologies in Table 1 , such as ELISA [ 36 , 70 ], nanoparticles-based immunoassays [ 71 ], surface-enhanced Raman spectroscopy [ 39 ], fluorescence [ 41 ], electrochemical biosensors [ 37 ], etc. ELISA is mainly used as a stopgap measure with the highest sensitivity in Aβ detection, but it cannot effectively distinguish monomers and oligomers.…”

Section: Resultsmentioning

confidence: 99%

Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay

Zhang

et al. 2021

J Nanobiotechnol

View full text Add to dashboard Cite

Aβ42 is one of the most extensively studied blood and Cerebrospinal fluid (CSF) biomarkers for the diagnosis of symptomatic and prodromal Alzheimer’s disease (AD). Because of the heterogeneity and transient nature of Aβ42 oligomers (Aβ42Os), the development of technologies for dynamically detecting changes in the blood or CSF levels of Aβ42 monomers (Aβ42Ms) and Aβ42Os is essential for the accurate diagnosis of AD. The currently commonly used Aβ42 ELISA test kits usually mis-detected the elevated Aβ42Os, leading to incomplete analysis and underestimation of soluble Aβ42, resulting in a comprised performance in AD diagnosis. Herein, we developed a dual-target lateral flow immunoassay (dLFI) using anti-Aβ42 monoclonal antibodies 1F12 and 2C6 for the rapid and point-of-care detection of Aβ42Ms and Aβ42Os in blood samples within 30 min for AD diagnosis. By naked eye observation, the visual detection limit of Aβ42Ms or/and Aβ42Os in dLFI was 154 pg/mL. The test results for dLFI were similar to those observed in the enzyme-linked immunosorbent assay (ELISA). Therefore, this paper-based dLFI provides a practical and rapid method for the on-site detection of two biomarkers in blood or CSF samples without the need for additional expertise or equipment. Graphical Abstract

show abstract

Section: Resultsmentioning

confidence: 99%

Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay

Zhang

et al. 2021

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…With the help of the magnetic separation, concentration effects of magnetic nanoparticles and high responsiveness of UCNPs, simple and sensitive detection of Aβ oligomers (LOD: 36 pM) could be achieved. It also can be applied for Aβ 40 and Aβ 42 oligomers detection in artificial CSF 122 . In view of the fact that dopamine nanomaterials inhibited the aggregation process of Aβ 123 , Liu et al first prepared bifunctional polydopamine nanospheres and then constructed a 'signal on' detection platform based on aptamers modified with fluorescent groups 124 .…”

Section: The Applications Of Aptamer In Aβ Detectionmentioning

confidence: 99%

Advances in aptamers against Aβ and applications in Aβ detection and regulation for Alzheimer's disease

Zheng¹,

Zhang²,

Zhao³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Alzheimer's disease (AD) is an irreversible neurodegenerative disease, causing profound social and economic implications. Early diagnosis and treatment of AD have faced great challenges due to the slow and hidden onset. β-amyloid (Aβ) protein has been considered an important biomarker and therapeutic target for AD. Therefore, non-invasive, simple, rapid and real-time detection methods for AD biomarkers are particularly favored. With the development of Aβ aptamers, the specific recognition between aptamers and Aβ plays a significant role in AD theranostics. On the one hand, aptamers are applied to construct biosensors for Aβ detection, which provides possibilities for early diagnosis of AD. On the other hand, aptamers are used for regulating Aβ aggregation process, which provides potential strategies for AD treatment. Many excellent reviews have summarized aptamers for neurodegenerative diseases or biosensors using specific recognition probes for Aβ detection applications in AD. In this review, we highlight the crucial role of the design, classification and applications of aptamers on Aβ detection as well as inhibition of Aβ aggregation for AD.

show abstract

“…As for the uorescent-based AD biosensors, series of biomarkers have been employed as an in vitro setting such as amyloid, [159][160][161] dopamine, [162][163][164][165][166][167][168][169][170] neurotoxin, 171 tau, 172 and ApoE4 DNA. 173 The major targeted analyte in this type of biosensor is AbO considered as the main culprit for AD initiation and progression.…”

Section: In Vitro Biosensing Systemmentioning

confidence: 99%

Clinically oriented Alzheimer's biosensors: expanding the horizons towards point-of-care diagnostics and beyond

et al. 2021

View full text Add to dashboard Cite

show abstract

Detection of Aβ oligomers based on magnetic-field-assisted separation of aptamer-functionalized Fe 3 O 4 magnetic nanoparticles and BaYF 5 :Yb,Er nanoparticles as upconversion fluorescence labels

Cited by 47 publications

References 35 publications

Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay

Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay

Advances in aptamers against Aβ and applications in Aβ detection and regulation for Alzheimer's disease

Clinically oriented Alzheimer's biosensors: expanding the horizons towards point-of-care diagnostics and beyond

Contact Info

Product

Resources

About